Search

Real-world data announced for adults with type 2 diabetes

Two analyses of the U.S. data from the EMPRISE real-world study show that Jardiance (empagliflozin) tablets was associated with a reduction in risk of hospitalization for heart failure compared with two other classes of glucose-lowering therapies in adult

Pioneers who inspire: Women in livestock

Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

Phase III study showed Ofev slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction

Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction

FDA accepts sNDA for children/adolescents with fibrosing ILD

U.S. FDA accepts sNDA for OFEV® (nintedanib) for the potential treatment of children and adolescents aged 6-17 with fibrosing interstitial lung disease

FDA approves the first treatment option for generalized pustular psoriasis flares in adults

Novel antibody shows potential to transform treatment of rare form of psoriasis

Boehringer Ingelheim unveils groundbreaking Research and Development space in St. Joseph, Mo.

Results for Jardiance® (empaglifozin) | BI US

Read more about JARDIANCE, a significant reduction of risk for cardiovascular death or hospitalization for heart failure.

New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

Full data announced in phase III EMPA-KIDNEY trial

The EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD)

INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases

Jardiance shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status

Foot & Mouth Disease: Know the Facts | Boehringer Ingelheim US

Click here to read more on how the US is planning to create a vaccine bank to guard against and prevent foot-and-mouth disease in livestock across the USA.

Vampire Bats & Rabies: A Potential New Threat | Boehringer Ingelheim US

Read more on the emerging threat of rabid vampire bats in the Southern US. Helping prevent this disease preserves the lives of livestock worldwide.

Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US

Find out more about how the use of JARDIANCE has proven to reduce the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%.

FDA Grants OFEV® (nintedanib) BTD for Chronic Fibrosing ILDs | Boehringer Ingelheim US

FDA grants Breakthrough Therapy Designation to OFEV for chronic fibrosing ILDs with a progressive phenotype. View ISI, PI and Med Guide.

Data Show Safety of Pradaxa® (dabigatran etexilate) in Children | Boehringer Ingelheim US

BI announces results from 2 pediatric studies of PRADAXA, presented at the ISTH Congress in Melbourne. View ISI, PI and Med Guide.

FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD

Clinical Development and Operations

Click here to find out more on how Boehringer Ingelheim is proud to offer a new 2-year Fellowship program within Clinical Operations.

Ridgefield, CT | BI Facilities

BI was established in Connecticut in 1971 and broke ground on September 1st, 1989 in Ridgefield. This site is home to the U.S. HQ of Boehringer Ingelheim

Shelter Bowl: These pets looking for a new home were the big winners

Dogs and cats in a pair of shelters were met with generous donations – and some footballs - thanks to a program committed to improving their future and well-being.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers